Incretin effect: GLP-1, GIP, DPP4

被引：74
|
作者：
Kazakos, Kyriakos [1 ]
机构：
[1] Alexander Technol Educ Inst Thessaloniki, Dept Nursing, Thessaloniki 55133, Greece
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2011年 / 93卷
关键词：
Diabetes mellitus; Incretin hormones; Beta cell; GLUCAGON-LIKE PEPTIDE-1; GASTRIC-INHIBITORY POLYPEPTIDE; DEPENDENT INSULINOTROPIC POLYPEPTIDE; METFORMIN-TREATED PATIENTS; EXENATIDE EXENDIN-4; GLYCEMIC CONTROL; 7-36; AMIDE; MYOCARDIAL-INFARCTION; IN-VITRO; GLUCOSE;
D O I：
10.1016/S0168-8227(11)70011-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The term incretin effect was used to describe the fact that oral glucose load produces a greater insulin response than that of an isoglycemic intravenous glucose infusion. This difference has been attributed to gastrointestinal peptides GLP-1 and GIP. Since incretin effect is reduced in subjects with type 2 diabetes, despite GLP-1 activity preservation, two forms of incretin-based treatment have emerged: GLP-1R agonists, administered subcutaneously and DPP-4 inhibitors, administered orally. There is a great interest whether incretin-based treatment will be associated with sustained long-term control and improvement in beta-cell function. The observation that GLP-1R agonists improve myocardial function and survival of cardiomyocytes highlights the need for further studies. Incretin-based therapies offer a new option and show great promise for the treatment of type 2 diabetes. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：S32 / S36
页数：5
相关论文
共 50 条
  • [31] SGLT2 INHIBITOR AND GLP-1 AGONIST OUTPERFORM DPP4 INHIBITOR FOR MORTALITY BENEFITS
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2018, 20 (07): : 1803 - 1803
  • [32] DPP4 Inhibition Improves Adipose Inflammation and Insulin Resistance via GLP-1 Independent Mechanisms
    Shah, Zubair
    Kampfrath, Thomas
    Deiuliis, Jeffrey
    Maiseyeu, Andrei
    Pineda, Colleen
    Ying, Zhekang
    Durairaj, Rekha
    Xu, Xiaohua
    Sun, Qinghua
    Rajagopalan, Sanjay
    CIRCULATION, 2010, 122 (21)
  • [33] Incretin-based antidiabetics: GLP-1 mimetics and DPP-IV inhibitors
    Gallwitz, B.
    DIABETOLOGIE UND STOFFWECHSEL, 2008, 3 (04) : 234 - +
  • [34] A comparative effect of DPP4 inhibitor and GLP-1 agonist on lipid profile among obese patients with DMT2
    Bostoganashvili, N.
    Mikadze, K.
    Kvanchakhadze, R.
    Tukvadze, S.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [35] Incretin-related drugs and cardiovascular events: A comparison of GLP-1 analogue and DPP-4 inhibitor
    Higashi, Yukihito
    JOURNAL OF CARDIOLOGY, 2017, 69 (3-4) : 508 - 510
  • [36] Inhibition of DPP-4 augments insulin secretion in response to GLP-1, GIP, PACAP and GRP in mice
    Ahrén, B
    Hughes, TE
    DIABETES, 2004, 53 : A339 - A339
  • [37] Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation
    Yabe, Daisuke
    Seino, Yutaka
    PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2011, 107 (02): : 248 - 256
  • [38] Biology of incretins: GLP-1 and GIP
    Baggio, Laurie L.
    Drucker, Daniel J.
    GASTROENTEROLOGY, 2007, 132 (06) : 2131 - 2157
  • [39] The classic incretin receptors for GLP-1 and GIP are essential for the sustained glucoregulatory actions of vildagliptin in mice
    Flock, G.
    Zhang, J. L.
    Duttaroy, A.
    Drucker, D. J.
    DIABETOLOGIA, 2006, 49 : 107 - 108
  • [40] Effect of the DPP-4 inhibitor vildagliptin on fasting plasma levels of intact GLP-1 and GIP in type 1 or type 2 diabetes
    Ligueros-Saylan, M.
    Kelley, D. E.
    He, Y. -L.
    Watson, C. A.
    Serra, D.
    Dunning, B. E.
    Deacon, C. F.
    Holst, J. J.
    Foley, J. E.
    DIABETOLOGIA, 2006, 49 : 406 - 407
12345